載入...
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) are commonly recommended anti-HER2 target...
Na minha lista:
| 發表在: | Signal Transduct Target Ther |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group UK
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6799843/ https://ncbi.nlm.nih.gov/pubmed/31637013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-019-0069-2 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|